CPTx
CPTx’s innovative platform technology and proprietary manufacturing capabilities position the company as a leader in developing next-generation in vivo genetic medicines using single-stranded DNA.
CPTx is focused on solving critical challenges in genetic medicine to unlock therapies that are safe, effective, and accessible. Our in vivo CAR-T platform program aims to bring life-saving cancer and autoimmune treatments to millions of patients for whom current therapies are inadequate, too complex, or too expensive.
We are also developing a revolutionary approach to gene delivery through our proprietary self-delivering gene carrier technology built with single-stranded DNA. This technology has the potential to expand the scope, adoption, and access to gene therapies by overcoming critical limitations of existing technologies.
CPTx’s proprietary synthesis processes and in-house manufacturing capabilities enable us to produce both long and short sequence, high-purity ssDNA at industrial scale. Our CDMO affiliate, gxstrands (www.gxstrands.com), has become a platform of choice for a growing base of pharma companies, who recognize ssDNA as a critical enabler for gene and cell therapy programs.
